VRDN Q1 2025 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72,000+0.0% YoY

Gross Profit

$72,000100.0% margin

Operating Income

-$94M-130369.4% margin

Net Income

-$87M-120711.1% margin

EPS (Diluted)

$-0.87

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$93M

Free Cash Flow

-$93M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$661M

Total Liabilities

$57M

Stockholders' Equity

$604M

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72,000	$72,000	+0.0%
Gross Profit	$72,000	$72,000	+0.0%
Operating Income	-$94M	-$56M	-67.9%
Net Income	-$87M	-$49M	-79.0%

Revenue Segments

Collaboration Revenue

$100,000100%